North Carolina-based Kymanox, a professional services organization that supports comprehensive drug development, recently announced it is expanding its device design and testing facility in King of Prussia.
Expansion will allow the company to enhance its laboratory testing capabilities and increase its current good practice (CGxP) footprint to meet projected demand over the next two years and broaden clients’ service offerings.
“We are happy to help our clients who are quickly resuming product development and commercialization programs as the overall market improves,” Stephen M. Perry, Kymanox CEO and founder, said. “This strategic, demand-based investment in our CGxP facility lets us support client and patient needs better. Life science leaders need to invest in new medicines that fill critical gaps, which includes a rising class of combination products for cell and gene therapies or ATMPs (advanced therapy medicinal products), including novel dose delivery methods to achieve better patient outcomes.”
The location’s design and testing team uses complex test methods requiring expertise in test engineering, fixture design, and bespoke test method validation. Once expansion is complete, the facility will support the assembly of advanced combination products to supply products for clinical studies, and will support the Kymanox’s expertise in sterilization technologies, methodologies, and validation.